Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Conclusion: Study is expected to open in the 4th quarter 2018 with first patient MLM-CAR44.1 infusion by the end of 2018. An update on study and enrollment status will be provided during the meeting.DisclosuresHajek: Takeda: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding. Locatelli: Bellicum: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Honoraria; bluebird bio: Consultancy. Bordignon: MolMed: Employment. Traversari: Molecular Medicine spa: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Carrabba, M. G., Casucci, M., Hudecek, M., Quintarelli, C., Briones, J., Hajek, R., Sierra, J., Locatelli, F., Einsele, H., Bordignon, C., Ciceri, F., Traversari, C. Tags: 801. Gene Therapy and Transfer Source Type: research